According to reliable sources, China-based clinical-stage biotechnology company, Sichuan Clover Biopharmaceuticals Inc. has announced the publication of the data from its Phase 1 clinical trials of S-Trimer COVID-19 vaccine in The Lancet, a peer-reviewed general medical journal.
For the record, the S-Trimer COVID-19 vaccine is Clover’s protein-based adjuvanted vaccine candidate that includes trimeric SARS-CoV-2 Spike (S) protein subunits. The vaccine utilizes the company’s proprietary Trimer-Tag© technology and is produced by a mammalian cell-culture based expression system.
If reports are to be believed, the clinical trial round included a double-blind, randomized, and placebo-controlled study which was conducted on 150 adult and elderly subjects. The trial round was aimed at interpreting the immunogenicity, reactogenicity, and safety of the drug in combination with the advanced adjuvants of GlaxoSmithKline plc or Dynavax Technologies Corporation.
These vaccine candidates were administered in two separate doses, with a time interval of three weeks between them. Moreover, the study found that Clover Biopharmaceutical’s vaccine was well tolerated and demonstrated stability at room temperature for as long as a period of at least two months.
Chairman of the Scientific Advisory Board for Clover’s COVID-19 Vaccine Program, Dr. Ralf Clemens, was reported saying that the positive outcomes of Phase 1 clinical trials mark a significant milestone in the global development of an effective COVID-19 vaccine. The findings of the study assure that the drug candidates are suitable for further clinical development, he added.
Sources aware of the development further cited that CEPI (Coalition for Epidemic Preparedness Innovations), a strategic collaboration among philanthropic and civil organizations for developing preventive measures towards future epidemics, has committed to invest around USD 328 million to support the Phase 2 and 3 clinical trials of Clover’s COVID-19 vaccine.
About Clover Biopharmaceuticals
Chengdu-headquartered Clover Biopharmaceutical’s primary operations revolve around the discovery, development, and commercialization of transformative biologic therapies. The research-based company’s main products include vaccines for oncological treatments as well as autoimmune diseases.
Source credits –